A 10-Year Single-Center Study of the Clinical Characteristics of Optic Neuritis-Related NMOSD, MS, and Double Seronegative Optic Neuritis, Together with Factors Predicting Visual Outcomes
- PMID: 36977296
- PMCID: PMC10056788
- DOI: 10.3390/vision7010016
A 10-Year Single-Center Study of the Clinical Characteristics of Optic Neuritis-Related NMOSD, MS, and Double Seronegative Optic Neuritis, Together with Factors Predicting Visual Outcomes
Abstract
The clinical characteristics of three types of optic neuritis (double seronegative optic neuritis; DN-ON, Neuromyelitis optica spectrum disorder-related optic neuritis; NMOSD-ON, and multiple sclerosis-related optic neuritis; MS-ON) were examined in order to identify factors that may affect good visual recovery in Thai patients. The study included patients diagnosed with three types of optic neuritis at Rajavithi Hospital between 2011 and 2020. Visual acuity at the end of 12 months was used as the treatment outcome. Multiple logistic regression analysis was used to evaluate potential predictors of good visual recovery. Of the 76 patients, 61 had optic neuritis, with DN-ON as the most common subtype (52.6%). MS-ON patients were significantly younger (28.3 ± 6.6 years, p = 0.002) and there was a female predominance in all subgroups (p = 0.076). NMOSD-ON patients had a significantly higher proportion of poor baseline VA (p < 0.001). None of the NMOSD-ON patients achieved 0.3 logMAR visual recovery in the 12-month period (p = 0.022). A delay in treatment with intravenous methylprednisolone (IVMP) for more than 7 days increased the risk of failure to gain 0.3 logMAR visual recovery by five times (OR 5.29, 95% CI 1.359-20.616, p = 0.016), with NMOSD-ON as the strongest predictor (OR 10.47, 95% CI; 1.095-99.993, p = 0.041). Early treatment with intravenous methylprednisolone may be important for achieving at least 0.3 logMAR visual recovery in Thai patients with optic neuritis.
Keywords: multiple sclerosis; neuromyelitis optica spectrum disorder; optic neuritis; visual acuity.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Beck R.W., Cleary P.A., Anderson Jr M.M., Keltner J.L., Shults W.T., Kaufman D.I., Buckley E.G., Corbett J.J., Kupersmith M.J., Miller N.R., et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N. Engl. J. Med. 1992;326:581–588. doi: 10.1056/NEJM199202273260901. - DOI - PubMed
-
- Wingerchuk D.M., Banwell B., Bennett J.L., Cabre P., Carroll W., Chitnis T., De Seze J., Fujihara K., Greenberg B., Jacob A., et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189. doi: 10.1212/WNL.0000000000001729. - DOI - PMC - PubMed
-
- Guo S., Jiang H., Jiang L., Peng J., Liu H., Wang J., Wei W. Factors influencing intravenous methylprednisolone pulse therapy in Chinese patients with isolated optic neuritis associated with AQP4 antibody-seropositive neuromyelitis optica. Sci. Rep. 2021;11:22229. doi: 10.1038/s41598-021-01109-5. - DOI - PMC - PubMed
-
- Akaishi T., Takeshita T., Himori N., Takahashi T., Misu T., Ogawa R., Kaneko K., Fujimori J., Abe M., Ishii T., et al. Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD. Front. Neurol. 2020;11:932. doi: 10.3389/fneur.2020.00932. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
